News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bioxel Pharma (BIP.V): First International Agreements for Docetaxel



5/13/2008 11:27:54 AM

SAINTE-FOY, QUEBEC--(Marketwire - May 13, 2008) - Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced it has extended its marketing presence in Asia through the execution of letters of intent with two major Korean generic drug companies for docetaxel active pharmaceutical ingredients. Each of these companies achieves sales of over US$1 billion on an annualized basis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES